176 related articles for article (PubMed ID: 36463765)
1. Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada.
Konstantelos N; Tourchian N; McCormack D; Lecce P; Tadrous M; Gomes T
Drug Alcohol Depend; 2023 Jan; 242():109705. PubMed ID: 36463765
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients.
Heikkinen M; Taipale H; Tanskanen A; Mittendorfer-Rutz E; Lähteenvuo M; Tiihonen J
Addiction; 2021 Aug; 116(8):1990-1998. PubMed ID: 33394527
[TBL] [Abstract][Full Text] [Related]
3. First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario.
Spithoff S; Turner S; Gomes T; Martins D; Singh S
Can Fam Physician; 2017 May; 63(5):e277-e283. PubMed ID: 28500210
[TBL] [Abstract][Full Text] [Related]
4. New pharmacotherapies for alcohol dependence.
Graham R; Wodak AD; Whelan G
Med J Aust; 2002 Jul; 177(2):103-7. PubMed ID: 12098353
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
Kranzler HR; Van Kirk J
Alcohol Clin Exp Res; 2001 Sep; 25(9):1335-41. PubMed ID: 11584154
[TBL] [Abstract][Full Text] [Related]
6. National trends in alcohol pharmacotherapy: Findings from an Australian claims database.
Morley KC; Logge W; Pearson SA; Baillie A; Haber PS
Drug Alcohol Depend; 2016 Sep; 166():254-7. PubMed ID: 27394934
[TBL] [Abstract][Full Text] [Related]
7. SAEM GRACE: Anti-craving medications for alcohol use disorder treatment in the emergency department: A systematic review of direct evidence.
Punia K; Scott W; Manuja K; Sabbineni M; Campbell K; Balodis IM; MacKillop J
Acad Emerg Med; 2024 May; 31(5):504-514. PubMed ID: 37735346
[TBL] [Abstract][Full Text] [Related]
8. Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Roos CR; Mann K; Witkiewitz K
Addict Biol; 2017 Nov; 22(6):1528-1539. PubMed ID: 27480445
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.
Kranzler HR; Soyka M
JAMA; 2018 Aug; 320(8):815-824. PubMed ID: 30167705
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
Donoghue K; Elzerbi C; Saunders R; Whittington C; Pilling S; Drummond C
Addiction; 2015 Jun; 110(6):920-30. PubMed ID: 25664494
[TBL] [Abstract][Full Text] [Related]
11. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.
Rubio G; Jiménez-Arriero MA; Ponce G; Palomo T
Alcohol Alcohol; 2001; 36(5):419-25. PubMed ID: 11524308
[TBL] [Abstract][Full Text] [Related]
12. Comparison of healthcare utilization among patients treated with alcoholism medications.
Mark TL; Montejano LB; Kranzler HR; Chalk M; Gastfriend DR
Am J Manag Care; 2010; 16(12):879-88. PubMed ID: 21348558
[TBL] [Abstract][Full Text] [Related]
13. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy.
Feeney GF; Connor JP; Young RM; Tucker J; McPherson A
Alcohol Alcohol; 2006; 41(3):321-7. PubMed ID: 16467406
[TBL] [Abstract][Full Text] [Related]
14. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.
Greenfield SF; Pettinati HM; O'Malley S; Randall PK; Randall CL
Alcohol Clin Exp Res; 2010 Oct; 34(10):1803-12. PubMed ID: 20645934
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy for alcohol use disorder among adults with medical disorders in Sweden.
Månsson A; Danielsson AK; Sjöqvist H; Glatz T; Lundin A; Wallhed Finn S
Addict Sci Clin Pract; 2024 May; 19(1):41. PubMed ID: 38764075
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.
Bouza C; Angeles M; Muñoz A; Amate JM
Addiction; 2004 Jul; 99(7):811-28. PubMed ID: 15200577
[TBL] [Abstract][Full Text] [Related]
17. Review of Evidence-Based Strategies to Treat Alcohol Use Disorder.
Worley J
J Psychosoc Nurs Ment Health Serv; 2021 Dec; 59(12):7-11. PubMed ID: 34846245
[TBL] [Abstract][Full Text] [Related]
18. Rationale for combining acamprosate and naltrexone for treating alcohol dependence.
Mason BJ
J Stud Alcohol Suppl; 2005 Jul; (15):148-56; discussion 140. PubMed ID: 16223066
[TBL] [Abstract][Full Text] [Related]
19. Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study.
Biernacka JM; Coombes BJ; Batzler A; Ho AM; Geske JR; Frank J; Hodgkinson C; Skime M; Colby C; Zillich L; Pozsonyiova S; Ho MF; Kiefer F; Rietschel M; Weinshilboum R; O'Malley SS; Mann K; Anton R; Goldman D; Karpyak VM
Neuropsychopharmacology; 2021 Nov; 46(12):2132-2139. PubMed ID: 34302059
[TBL] [Abstract][Full Text] [Related]
20. [Meta-analysis of pharmacological therapy with acamprosate, naltrexone, and disulfiram--a systematic review].
Petrov I; Krogh J; Nordentoft M
Ugeskr Laeger; 2011 Nov; 173(48):3103-9. PubMed ID: 22118653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
